Mpox Vaccine gets approval

The World Health Organization (WHO) has granted approval for the use of an mpox vaccine for the first time, stating that this decision will enhance “timely and increased access” for millions at risk in Africa, where the current outbreak has affected over 20,000 individuals this year.

The MVA-BN vaccine, developed by the Danish pharmaceutical firm Bavarian Nordic, received prequalification from the WHO on Friday and has already been authorized for use in adults in Europe and the United States. This WHO endorsement is expected to expedite access for millions, aiming to reduce transmission and manage the outbreak effectively.

Tedros Adhanom Ghebreyesus, WHO’s Director-General, emphasized that the prequalification of this vaccine marks a significant advancement in combating the mpox virus in Africa and for future efforts.

“We must now urgently scale up procurement, donations, and distribution to guarantee equitable access to vaccines in the areas of greatest need, alongside other public health measures, to prevent infections, halt transmission, and save lives,” Mr. Ghebreyesus stated.

Mpox Vaccine Administration

The MVA-BN vaccine is administered in two doses to individuals aged 18 and older, spaced four weeks apart, and boasts an estimated effectiveness of 82 percent. For infants, young children, pregnant women, and immunocompromised individuals, the vaccine may be utilized when the advantages outweigh the potential risks.

In cases of limited vaccine supply, the health organization advises administering single doses, which have a 76 percent effectiveness rate. The WHO indicated that the prequalification of this vaccine will facilitate faster procurement by governments and international organizations, including the vaccine alliance Gavi and the UN Children’s Fund (UNICEF). Additionally, it may expedite regulatory approvals in countries around the globe.